Further to earlier communication dated 12 October 2026, Sun Pharmaceutical Industries has informed that the Company has today, i.e., 26 October 2026, completed the allotment, on a private placement basis, of rated, listed, unsecured, redeemable, non-convertible debentures (NCDs) having an aggregate face value of INR 7,816 crore, comprising: 1. Series A NCDs having an aggregate face value of INR 2,003 crore; and 2. Series B NCDs having an aggregate face value of INR 5,813 crore. The base issue size of INR 7,000 crore was fully subscribed and, based on the bids received and accepted, the Company exercised the greenshoe option to the extent of ?816 crore, out of the greenshoe option of up to INR 3,000 crore. The details required under Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 are enclosed as Annexure A.
The above information is a part of company’s filings submitted to BSE.
